Respiratory Virus Prophylaxis in Congenital Heart Disease

References

• Borchers AT , ChangC, GershwinME, GershwinLJ . Respiratory syncytial virus – a comprehensive review . Clin. Rev. Allergy Immunol.45 ( 3 ), 331 – 379 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Eiland LS . Respiratory syncytial virus: diagnosis, treatment and prevention . J. Pediatr. Pharmacol. Ther.14 ( 2 ), 75 – 85 ( 2009 ).
   PubMedGoogle Scholar
• Rezaee F , LinfieldDT, HarfordTJ, PiedimonteG . Ongoing developments in RSV prophylaxis: a clinician’s analysis . Curr. Opin. Virol.24, 70 – 78 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Mazur NI , Martinon-TorresF, BaraldiEet al. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics . Lancet Respir. Med.3 ( 11 ), 888 – 900 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Rudan I , Boschi-PintoC, BiloglavZ, MulhollandK, CampbellH . Epidemiology and etiology of childhood pneumonia . Bull. World Health Organ.86 ( 5 ), 408 – 416 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Scheltema NM , GentileA, LucionFet al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series . Lancet Glob. Health5 ( 10 ), e984 – e991 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Shi T , McallisterDA, O’brienKLet al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study . Lancet390 ( 10098 ), 946 – 958 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Drysdale SB , GreenCA, SandeCJ . Best practice in the prevention and management of paediatric respiratory syncytial virus infection . Ther. Adv. Infect. Dis.3 ( 2 ), 63 – 71 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Falsey AR , HennesseyPA, FormicaMA, CoxC, WalshEE . Respiratory syncytial virus infection in elderly and high-risk adults . N. Engl. J. Med.352 ( 17 ), 1749 – 1759 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Carpenter TC , StenmarkKR . Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis . Pediatr. Infect. Dis. J.23 ( 1 Suppl. ), S33 – S40 ( 2004 ).
   Web of Science ®Google Scholar
• Munywoki PK . Influence of age, severity of infection, and co-infection on the duration of respiratory syncytial virus (RSV) shedding . Epidemiol. Infect.143 ( 4 ), 804 – 812 ( 2015 ).
   Web of Science ®Google Scholar
• Mizuta K , AbikoC, AokiYet al. Seasonal patterns of respiratory syncytial virus, influenza A virus, human metapneumovirus, and parainfluenza virus type 3 infections on the basis of virus isolation data between 2004 and 2011 in Yamagata, Japan . Jpn. J. Infect. Dis.66 ( 2 ), 140 – 145 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Stockman LJ , BrooksWA, StreatfieldPKet al. Challenges to evaluating respiratory syncytial virus mortality in Bangladesh, 2004–2008 . PLoS ONE8 ( 1 ), e53857 ( 2013 ).
   Web of Science ®Google Scholar
• Turner TL , KoppBT, PaulG, LandgraveLC, HayesD, ThompsonR . Respiratory syncytial virus: current and emerging treatment options . Clinicoecon. Outcomes Res.6, 217 – 225 ( 2014 ).
   PubMedGoogle Scholar
• Rogovik AL , CarletonB, SolimanoA, GoldmanR . Palivizumab for the prevention of respiratory syncytial virus infection . Can. Fam. Physician56, 769 – 772 ( 2010 ).
   Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee . Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection . Pediatrics134 ( 2 ), 415 – 420 ( 2014 ).
   PubMedGoogle Scholar
• Feltes TF , CabalkaAK, MeissnerHCet al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease . J. Pediatr.143 ( 4 ), 532 – 540 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Resch B , SommerC, NuijtenMJet al. Cost–effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria . Pediatr. Infect. Dis. J.31 ( 1 ), e1 – e8 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bentley A , FilipovicI, GoochK, BüschK . A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom . Health Econ. Rev.3 ( 1 ), 18 ( 2013 ).
   PubMedGoogle Scholar
• Hussman JM , LanctotKL, PaesB . The cost–effectiveness of palivizumab in congenital heart disease: a review of the current evidence . J. Med. Econ.16 ( 1 ), 115 – 124 ( 2013 ).
   PubMedGoogle Scholar
• Harris KC , AnisAH, CrosbyMC, CenderLM, PottsJE, HumanDG . Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective . Can. J. Cardiol.27 ( 4 ), 523.e11 – 523.e15 ( 2011 ).
   Web of Science ®Google Scholar
• Majer I , Pichardo-PinaCA, Sanchez-CasillasJL, SchmidtR, VoP . Cost–effectiveness of palivizumab in children with congenital heart disease in Mexico . Value Health18 ( 7 ), A830 ( 2015 ).
   Web of Science ®Google Scholar
• Nuijten M , LebmeierM, WittenbergW . Cost–effectiveness of palivizumab in children with congenital heart disease in Germany . J. Med. Econ.12 ( 4 ), 301 – 308 ( 2009 ).
   PubMedGoogle Scholar
• Ambrose CS , ChenX, KumarVR . A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children . Hum. Vaccin. Immunother.10 ( 10 ), 2785 – 2788 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Smart KA , LanctotKL, PaesBA . The cost–effectiveness of palivizumab: a systematic review of the evidence . J. Med. Econ.13 ( 3 ), 453 – 463 ( 2010 ).
   PubMedGoogle Scholar
• Li A , WangDY, LanctotKL, MitchellI, PaesBA . Comparing first- and second-year palivizumab prophylaxis in patients with hemodynamically significant congenital heart disease in the CARESS database (2005–2015) . Pediatr. Infect. Dis. J.36 ( 5 ), 445 – 450 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Utidjian L , HoganA, MichelJet al. Clinical decision support and palivizumab: a means to protect from respiratory syncytial virus . Appl. Clin. Inform.6 ( 4 ), 769 – 784 ( 2015 ).
   Google Scholar
• Hoffman JIE . The global burden of congenital heart disease . Cardiovasc. J. Afr.24 ( 4 ), 141 – 145 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Van Der Linde D , KoningsEE, SlagerMAet al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis . J. Am. Coll. Cardiol.58 ( 21 ), 2241 – 2247 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Knowles RL , RidoutD, CroweSet al. Ethnic and socioeconomic variation in incidence of congenital heart defects . Arch. Dis. Child.102 ( 6 ), 496 – 502 ( 2017 ).
   Web of Science ®Google Scholar
• Kim AY , JungSY, ChoiJYet al. Retrospective multicenter study of respiratory syncytial virus prophylaxis in Korean children with congenital heart diseases . Korean Circ. J.46 ( 5 ), 719 – 726 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Chang RK , ChenAY . Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease . Pediatr. Cardiol.31 ( 1 ), 90 – 95 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Jung JW . Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey . Korean J. Pediatr.54 ( 5 ), 192 – 196 ( 2011 ).
   PubMedGoogle Scholar
• Medrano Lopez C , Garcia-GueretaL . Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era: the Spanish 4-season civic epidemiologic study . Pediatr. Infect. Dis. J.29 ( 12 ), 1077 – 1082 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Meberg A , BruuAL . Respiratory syncytial virus infections in congenital heart defects – hospitalizations and costs . Acta Paediatr.95 ( 4 ), 404 – 406 ( 2006 ).
   Web of Science ®Google Scholar
• Straňák Z , SalibaE, KosmaPet al. Predictors of RSV LRTI hospitalization in infants born at 33 to 35 weeks gestational age: a large multinational study (PONI) . PLoS ONE11 ( 6 ), e0157446 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Simoes EA , Carbonell-EstranyX, FullartonJRet al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP study . Respir. Res.9, 78 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Blanken MO , KoffijbergH, NibbelkeEE, RoversMM, BontL . Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study . PLoS ONE8 ( 3 ), e59161 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Tulloh RMR , Medrano-LopezC, ChecchiaPAet al. CHD and respiratory syncytial virus: global expert exchange recommendations . Cardiol. Young27 ( 8 ), 1504 – 1521 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Esposito S , SaliceP, BosisSet al. Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infection . BMC Infect. Dis.10, 305 ( 2010 ).
   Web of Science ®Google Scholar
• Sen-Chowdhry S , MckennaWJ . Sudden cardiac death in the young: a strategy for prevention by targeted evaluation . Cardiology105 ( 4 ), 196 – 206 ( 2006 ).
   Web of Science ®Google Scholar
• Yitshak-Sade M , YudovitchD, NovackV, TalA, KloogI, GoldbartA . Air pollution is associated with bronchiolitis hospitalization in southern Israel . Ann. Am. Thorac. Soc.14 ( 12 ), 1796 – 1802 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Hall CB , GeimanJM, DouglasRGJr, MeagherMP . Control of nosocomial respiratory syncytial viral infections . Pediatrics62 ( 5 ), 728 – 732 ( 1978 ).
   PubMed Web of Science ®Google Scholar
• Garner JS . Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee . Infect. Control Hosp. Epidemiol.17 ( 1 ), 53 – 80 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• [No author listed] . Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn . Pediatrics102 ( 5 ), 1211 – 1216 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Saadah LM , ChedidFD, SohailMR, NazzalYM, Al KaabiMR, RahmaniAY . Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model . Pharmacotherapy34 ( 3 ), 251 – 259 ( 2014 ).
   Web of Science ®Google Scholar
• Alexander PM , EastaughL, RoyleJ, DaleyAJ, ShekerdemianLS, PennyDJ . Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease . J. Paediatr. Child Health48 ( 5 ), 395 – 401 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kapikian AZ , MitchellRH, ChanockRM, ShvedoffRA, StewartCE . An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine . Am. J. Epidemiol.89 ( 4 ), 405 – 421 ( 1969 ).
   PubMed Web of Science ®Google Scholar
• Sandritter TL , KrausDM . Respiratory syncytial virus-immunoglobulin intravenous (RSV-IGIV) for respiratory syncytial viral infections: part I . J. Pediatr. Health Care11 ( 6 ), 284 – 291 ; quiz 292–283 ( 1997 ).
   PubMedGoogle Scholar
• [No author listed] . Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group . Pediatrics99 ( 1 ), 93 – 99 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Mejias A , RamiloO . Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants . Biologics2 ( 3 ), 433 – 439 ( 2008 ).
   PubMedGoogle Scholar
• Groothuis JR , SimoesEA, LevinMJet al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group . N. Engl. J. Med.329 ( 21 ), 1524 – 1530 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Driver LC , OertelMD . Synagis: an anti-RSV monoclonal antibody . Pediatr. Nurs.25 ( 5 ), 527 – 530 ( 1999 ).
   Google Scholar
• Roberts JN , GrahamBS, KarronRAet al. Challenges and opportunities in RSV vaccine development: meeting report from FDA/NIH workshop . Vaccine34 ( 41 ), 4843 – 4849 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• RSV vaccine and mAb snapshot. PATH ( 2017 ). www.path.org/publications/files/CVIA_rsv_snapshot_final_0917r.pdf
   Google Scholar
• Collins PL , MeleroJA . Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years . Virus Res.162 ( 1–2 ), 80 – 99 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Kaaijk P , LuytjesW, RotsNY . Vaccination against RSV: is maternal vaccination a good alternative to other approaches?Hum. Vaccin. Immunother.9 ( 6 ), 1263 – 1267 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ogilvie MM , VathenenAS, RadfordM, CoddJ, KeyS . Maternal antibody and respiratory syncytial virus infection in infancy . J. Med. Virol.7 ( 4 ), 263 – 271 ( 1981 ).
   PubMed Web of Science ®Google Scholar
• Chu HY , SteinhoffMC, MagaretAet al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh . J. Infect. Dis.210 ( 10 ), 1582 – 1589 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Van Erp EA , Van KasterenPB, GuichelaarTet al. In vitro enhancement of respiratory syncytial virus infection by maternal antibodies does not explain disease severity in infants . J. Virol.91 ( 21 ), e00851 – 17 ( 2017 ).
   Web of Science ®Google Scholar
• Chu HY , TielschJ, KatzJet al. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal . J. Clin. Virol.95, 90 – 95 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Higgins D , TrujilloC, KeechC . Advances in RSV vaccine research and development: a global agenda . Vaccine34 ( 26 ), 2870 – 2875 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Modjarrad K , GiersingB, KaslowDC, SmithPG, MoorthyVS . WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23–24 March 2015 . Vaccine34 ( 2 ), 190 – 197 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Graham BS . Vaccine development for respiratory syncytial virus . Curr. Opin. Virol.23, 107 – 112 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Villafana T , FalloonJ, GriffinMP, ZhuQ, EsserMT . Passive and active immunization against respiratory syncytial virus for the young and old . Expert Rev. Vaccines16 ( 7 ), 737 – 749 ( 2017 ).
   PubMed Web of Science ®Google Scholar